Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
3.945
-0.055 (-1.38%)
Streaming Delayed Price
Updated: 10:27 AM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
111,829
Open
4.000
Bid (Size)
3.930 (12)
Ask (Size)
3.950 (9)
Prev. Close
4.000
Today's Range
3.880 - 4.000
52wk Range
2.640 - 7.450
Shares Outstanding
52,346,231
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
October 28, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
October 16, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Performance
YTD
-42.32%
-42.32%
1 Month
+8.68%
+8.68%
3 Month
-15.88%
-15.88%
6 Month
-1.38%
-1.38%
1 Year
+39.89%
+39.89%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 02, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
June 17, 2024
Via
Benzinga
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
September 19, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
August 27, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
June 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
June 13, 2024
Via
InvestorPlace
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
May 31, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Crude Oil Gains 1%; GameStop Shares Plunge
May 17, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 17, 2024
Via
Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 17, 2024
Via
InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
May 17, 2024
Via
Benzinga
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 17, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
May 13, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
April 24, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 11, 2024
Via
Benzinga
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
April 02, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.